Tasly Pharmaceutical Group Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000001C81
  • SHG: 600535
CNY
13.95
-0.12 (-0.85%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

11.07 M

Shareholding (Jun 2017)

FII

0.02%

Held by 1 FIIs

DII

99.98%

Held by 0 DIIs

Promoter

0.00%

iScoreScore

Dashboard

1

With ROE of 7.63%, it has a very attractive valuation with a 1.55 Price to Book Value

  • Over the past year, while the stock has generated a return of -9.98%, its profits have fallen by -1%
  • At the current price, the company has a high dividend yield of 2.4
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 23,035 Million (Large Cap)

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.02%

stock-summary
Debt Equity

-0.10

stock-summary
Return on Equity

7.63%

stock-summary
Price to Book

1.80

Revenue and Profits:
Net Sales:
2,036 Million
(Quarterly Results - Jun 2026)
Net Profit:
520 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.9%
0%
1.9%
6 Months
-1.41%
0%
-1.41%
1 Year
-11.2%
0%
-11.2%
2 Years
0%
0%
0.0%
3 Years
2.8%
0%
2.8%
4 Years
44.26%
0%
44.26%
5 Years
1.75%
0%
1.75%

Tasly Pharmaceutical Group Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-6.02%
EBIT Growth (5y)
1.96%
EBIT to Interest (avg)
26.04
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.59
Tax Ratio
18.31%
Dividend Payout Ratio
41.91%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
10.65%
ROE (avg)
10.17%

Valuation key factors

Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.55
EV to EBIT
13.53
EV to EBITDA
10.77
EV to Capital Employed
1.61
EV to Sales
2.22
PEG Ratio
NA
Dividend Yield
2.35%
ROCE (Latest)
11.90%
ROE (Latest)
7.63%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2017stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is -5.94% vs 12.41% in Mar 2026",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 42.62% vs 429.94% in Mar 2026",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,036.30",
          "val2": "2,164.80",
          "chgp": "-5.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "695.80",
          "val2": "568.00",
          "chgp": "22.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.20",
          "val2": "3.30",
          "chgp": "27.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-26.00",
          "val2": "14.90",
          "chgp": "-274.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "520.00",
          "val2": "364.60",
          "chgp": "42.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "285.20%",
          "val2": "209.20%",
          "chgp": "7.60%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -3.17% vs -2.03% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 23.54% vs -15.49% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8,150.10",
          "val2": "8,416.60",
          "chgp": "-3.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,824.70",
          "val2": "1,934.80",
          "chgp": "-5.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "34.00",
          "val2": "64.80",
          "chgp": "-47.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "104.30",
          "val2": "-329.70",
          "chgp": "131.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,061.30",
          "val2": "859.10",
          "chgp": "23.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "166.90%",
          "val2": "170.20%",
          "chgp": "-0.33%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQstock-summary

Jun'26
Mar'26
Change(%)
Net Sales
2,036.30
2,164.80
-5.94%
Operating Profit (PBDIT) excl Other Income
695.80
568.00
22.50%
Interest
4.20
3.30
27.27%
Exceptional Items
-26.00
14.90
-274.50%
Consolidate Net Profit
520.00
364.60
42.62%
Operating Profit Margin (Excl OI)
285.20%
209.20%
7.60%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2026 is -5.94% vs 12.41% in Mar 2026

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is 42.62% vs 429.94% in Mar 2026

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
8,150.10
8,416.60
-3.17%
Operating Profit (PBDIT) excl Other Income
1,824.70
1,934.80
-5.69%
Interest
34.00
64.80
-47.53%
Exceptional Items
104.30
-329.70
131.63%
Consolidate Net Profit
1,061.30
859.10
23.54%
Operating Profit Margin (Excl OI)
166.90%
170.20%
-0.33%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -3.17% vs -2.03% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 23.54% vs -15.49% in Dec 2024

stock-summaryCompany CV
About Tasly Pharmaceutical Group Co., Ltd. stock-summary
stock-summary
Tasly Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Footer loading